Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Sushma Kumar et al.|The Lancet HIV|2018Cited by 145
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trialsAlain Amstutz, Matthias Briel, Benjamin Speich et al.|The Lancet Respiratory Medicine|2023Cited by 124
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Christine Katlama, Jean‐Michel Molina et al.|The Lancet HIV|2023Cited by 31
REACTing: the French response to infectious disease crisesJean-François Delfraissy, Yves Lévy, Yazdan Yazdanpanah|The Lancet|2016Cited by 18
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohortSarah Tubiana, Catherine Chirouze, Charles Burdet et al.|Journal of Infection|2021Cited by 7